论文部分内容阅读
目的脑梗死治疗重点是消除自由基,提高脑神经恢复功能,加快脑部循环与代谢速度,本研究探讨脑梗死患者应用依达拉奉与奥扎格雷钠联合治疗的临床效果。方法选择于2015年6月至2016年11月间洛阳石化医院收治的85例脑梗死患者作为研究对象,随机分为观察组(44例)和对照组(41例)。观察组给予依达拉奉与奥扎格雷钠联合治疗,对照组给予奥扎格雷钠治疗。两组患者均治疗14 d。对比两组治疗后临床疗效及治疗前、治疗2周、1个月的美国国立卫生院卒中量表(NIHSS)评分与日常生活活动能力量表(Barthel指数)。结果观察组治疗总有效率(97.73%)明显高于对照组(82.93%),差异有统计学意义(χ2=4.624,P<0.05)。治疗前,两组NIHSS评分和Barthel指数比较,差异无统计学意义(P>0.05)。治疗2周与1个月后,两组患者NIHSS评分明显下降,观察组明显低于对照组(P<0.05);两组患者Barthel指数均较治疗前明显升高,且观察组明显高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者均未发生明显不良反应。结论使用依达拉奉与奥扎格雷钠联合治疗脑梗死具有明显疗效,能够改善患者的神经功能,提高日常生活能力,可在临床推广。
The purpose of the treatment of cerebral infarction focus is to eliminate free radicals, improve brain nerve recovery, speed up the brain circulation and metabolic rate, the study of cerebral infarction patients with edaravone and ozagrel sodium combined treatment of clinical effect. Methods Eighty-five patients with cerebral infarction admitted to Luoyang Petrochemical Hospital from June 2015 to November 2016 were randomly divided into observation group (44 cases) and control group (41 cases). The observation group was treated with edaravone and ozagrel sodium, while the control group was given ozagrel sodium. Both groups were treated for 14 days. The clinical efficacy and the NIHSS score and Barthel index of the two groups before treatment, two weeks and one month after treatment were compared. Results The total effective rate of observation group (97.73%) was significantly higher than that of control group (82.93%), the difference was statistically significant (χ2 = 4.624, P <0.05). Before treatment, there was no significant difference between the two groups in NIHSS score and Barthel index (P> 0.05). After two weeks and one month of treatment, the NIHSS scores of the two groups were significantly decreased, the observation group was significantly lower than the control group (P <0.05); Barthel index was significantly higher in both groups than before treatment, and the observation group was significantly higher than the control group Group, the difference was statistically significant (P <0.05). After treatment, no significant adverse reactions occurred in both groups. Conclusion The combination of edaravone and ozagrel sodium has a significant therapeutic effect on cerebral infarction, which can improve the neurological function and improve the daily living ability of patients. It can be used clinically.